1,614.30
+0.12%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Poly Medicure
Its shares trade on NSE under the ticker POLYMED.NS. It has been listed since 5 December 2011. In the fiscal year to 31 March 2026, it reported revenue of ₹18.75bn and net income of ₹3.22bn. At that date it held total assets of ₹39.19bn and shareholders' equity of ₹31.06bn.
Poly Medicure Ltd. engages in the provision and sales of medical devices. The company is headquartered in Faridabad, Haryana. The company went IPO on 2011-12-05. The firm is primarily in the business of manufacture and sale of medical devices. The firm offers a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, covid care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. The company supplies its products to approximately 120 countries, in Europe, Africa, Americas, Australia, and Asia. Its products include suction control valve, safety arterial cannula, VTM Kit, VLTM kit, blood collection needle with flashback, and pre-filled syringes. The firm operate nine manufacturing facilities across India, China, Egypt, and Italy. In India, it operates six manufacturing facilities, four of which are situated at Faridabad (Haryana), and one each in Jaipur (Rajasthan) and Haridwar (Uttarakhand).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 5 Dec 2011
- Employees
- 2,339
- Website
- polymedicure.com ↗
Leadership
Pay as last reported
- Mr. Devendra MehtaNon-Executive and Non-Independent Chairman of the Board₹2.3m
- Shri. Naresh VijayvargiyaChief Financial Officer
- Shri. Avinash ChandraCompliance Officer, Company Secretary
- Shri. Himanshu BaidManaging Director, Executive Director₹214.2m
- Shri. Rishi BaidJoint Managing Director, Executive Director, since 2014₹209.3m
- Shri. Vishal BaidExecutive Director, since 2025
- Mr. Pankaj GuptaExecutive Director, since 2025
- Shri. Ravi PrakashDeputy Company Secretary
- Shri. Jugal BaidNon Executive and Non Independent Director₹2.1m
- Shri. Alessandro BalboniNon-Executive and Non Independent Director₹28.2m
- Mr. Vimal BhandariNon-Executive Independent Director₹1.4m
- Shri. Vishal GuptaNon-Executive Independent Director₹950,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 44
- Social
- 78
- Governance
- 49
- Direct emissions (scope 1)
- 2,319.85 t
- Energy emissions (scope 2)
- 33,962.28 t
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Poly Medicure employs 2339 full-time employees across nine manufacturing facilities in India, China, Egypt, and Italy.
- The company supplies medical devices to approximately 120 countries including Europe, Africa, Americas, Australia, and Asia.
- Poly Medicure offers a diverse portfolio including infusion therapy, oncology, anesthesia, and respiratory care products.
Weaknesses
- Poly Medicure's manufacturing facilities in Faridabad, Jaipur, and Haridwar are located in India, limiting global production diversity.
- The company's product portfolio includes veterinary medical devices, which may not align with core healthcare focus.
- Poly Medicure's presence in China and Egypt may face geopolitical challenges in manufacturing.
Opportunities
- Poly Medicure can expand its medical device sales in emerging markets like Africa and Asia with its current 120-country supply network.
- The growing demand for infusion therapy and oncology devices presents a significant opportunity for Poly Medicure.
- Poly Medicure's manufacturing facilities in China and Italy could be leveraged for increased production capacity.
Threats
- Poly Medicure faces competition from other medical device manufacturers in the global market.
- The company's reliance on manufacturing facilities in China and Egypt could be disrupted by geopolitical tensions.
- Poly Medicure's product offerings like VTM Kit and blood collection needles may face regulatory challenges in key markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.